Ureteral access sheath: omitting versus placing a stent after ureteroscopy

Access Sheath and stENT Trial

Not applicable Interventional University of Michigan · NCT07297953

We will test if leaving out a ureteral stent after ureteroscopy with an access sheath works as well as placing a stent for pre-stented adults with kidney or ureteral stones.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment184 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity of Michigan Academic / other
Locations1 site (Ann Arbor, Michigan)
Trial IDNCT07297953 on ClinicalTrials.gov

What this trial studies

Patients who consent will complete baseline patient-reported outcome questionnaires and undergo ureteroscopy using a ureteral access sheath. The operating urologist will grade the ureter for injury using the Post-Ureteroscopic Lesion Scale (PULS), and only those with PULS 0 or 1 will be randomized 1:1 to stent omission or stent placement. When a stent is placed, the type and whether a tether (string) is left will be left to the surgeon's discretion. The trial will compare patient-reported pain outcomes (PROMIS Pain Interference and Pain Intensity) and 30-day healthcare utilization between the two arms.

Who should consider this trial

Good fit: Ideal candidates are adults who are pre-stented and planned for unilateral ureteroscopy with a ureteral access sheath for kidney or ureteral stones and who can complete study surveys and follow-up.

Not a fit: Patients with intraoperative ureteral injury (PULS ≥2), ureteral strictures, certain anatomical abnormalities, pregnancy, or those not pre-stented are unlikely to benefit from the stent-omission approach tested here.

Why it matters

Potential benefit: If successful, some patients could avoid the discomfort and inconvenience of a ureteral stent while keeping similar pain and quality-of-life outcomes and reducing short-term healthcare use.

How similar studies have performed: Previous randomized and observational studies have suggested stent omission can be safe and reduce stent-related symptoms after uncomplicated ureteroscopy, though results vary by patient selection and technique.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Planned ureteroscopy using a Ureteral Access Sheath (UAS) for treatment of unilateral kidney and/or ureteral stones in patients that have an existing ureteral stent (pre-stented)
* Planned treatment of unilateral renal and/or ureteral stones, in a single procedure.
* Renal stone defined as only renal location of stone(s)
* Ureteral stone defined as ureteral only location of stone(s)
* Ureteral and renal stone(s)
* No evidence of significant ureteral injury on intra-operative assessment (Post-Ureteroscopy Lesion Scale (PULS) Grade 0 or 1)
* Ability and willingness to complete and adhere to survey questions and responses throughout study duration.

Exclusion Criteria:

* Pregnancy
* Ureteric injury during ureteroscopy (PULS ≥ Grade 2)
* Evidence of ureteral stricture
* Anatomical abnormalities (e.g., solitary, horseshoe, fused crossed ectopia, pelvic kidney, urinary diversion)
* Known planned secondary or staged procedure
* Indwelling nephrostomy tube
* Bilateral ureteroscopy

Where this trial is running

Ann Arbor, Michigan

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Kidney StoneUreteral StoneUreteral stentUreteroscopy and lithotripsySurveysQuality of life
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.